INTRODUCTION:

The word AIDS stand for acquired immunodeficiency deficiency syndrome. The public understanding of AIDS as a highly critical acute illness with a rapid downward trajectory was crystallized nevertheless, as early as 1991 in the medical sociology literature and nursing in that a few investigators were already discussing HIV/AIDS as a chronic illness^1,2. I short afterwards a number of psychological investigation of small groups of long term AIDS survivor’s appeared letter, although of these case we're still seen as the infrequent exception.³infection with HIV or having AIDS is something that should not be hidden since then it was not until the advent of protease inhibitors in the 1996 in that which adhered in era of highly active antireovira therapy (HAART)^4.The person who survive from these has opportunity for a second Life.⁵in that some of advanced stages of that disease.⁶Here, in unite state. Newly treatments advanced have had profound impact on illness trajectory and many peoples life expectancy of these people who is infected⁷. Many countries have allowed AIDS to reach catastrophic level⁸. In United States has been not allowing infected person to choose any new treatment^9-11. Some proof supporting their actions remains indecisive^12,13. Some country like African, Americans low levels of education and less likely used the new therapies.^14-17

Psyological Thinking and Changes:

Aids is effect on mental state of infected person. The peason may undergo depression. The people who have HIV/AIDS can also effect on their nervous system and can be lead to changes in their behaviour. The mental health could be improved by acquisition of social support like friends and family provide helpful links like education, health care and social support should enable the HIV positive person to feel less depressed, lonely or anxious. The person should be visit the health care center. The person need support from families members, is important for patient adherence to medical regimens. [fennel et al., 1994, Hart et al 1990; Stuart and Davis, 1972; Wilcox et al., 1965].^18-21 The infected person also require self-care(including self-monitoring of symptoms) on body ,since most of the day to day management of illness takes place outside formal health institution or facilities. Chronic conditions also carry some degree of stigma.²² AIDS is a sexually transmitted infections. It can be spread through the contact with infected blood or from mother to child during pregnancy, child birth or breast- feeding. AIDS is responsible for changes the behaviour of infected person and also responsible for their changing daily routine like feeling sad or anxious often or all the time. Do not want to do any activities that used to be fun, feeling like irritable, frustrating, or restless. Sometimes, waking up too early or less than usual or having no appetite. Feel like guilty, worthless or helpless. Sometimes, in depression thinking about suicide or hurting yourself. These all symptoms can be minimizing by bring their family support (e.g parent, worker and partner). Many infected individuals benefitting HAART are also cautiously considering returning to work to improve their financial situation, to become more socially integrated, to feel more productive, and to counteract boredom.²³ (leaks H-M, Le G, unpublished data) those considering beginning a relationship to face many of the same dilemmas confront before HAART, including the anxiety of disclosing one's HIV status, infecting one's partner and becoming re- infected.^23,24

Causes:

Research has worked hard to comprehend the AIDS epidemic since its inception nature of the disease and its manifestation. The human immunodeficiency virus (HIV) is the causative agent (HIV). The two of them HIV-1 and HIV-2 are two most common kinds of HIV^{25, 26}. Belong to a group of primate antiviruses some of which infect African green monkey. Sivagm monkey, sooty monkeys called mangabeys (sivsm), Sykes (sivmnd), mandrills (sivmnd) sivsyk monkey, and SIVcpz is a virus that affects chimps.²⁷ I will go into the structure and molecular mechanisms. HIV's characteristics, as well as other lentiviruses in primates in their effects the phylogenetic tree and variability and talk about it AIDS virus has a recent simian origin, according to one theory. Molecular features of HIV visions have a virus capsid, which consists the primary caused protein the nucleocapsid protein and the nucleocapsid protein, the three diploid single stranded RNA genomes. Protease, reverse transcriptase, and viral enzyme integrated the presence of reverse transcription is a sign of a healthy cell. This enzyme is capable of transcribing retroviruses DNA. RNA from the genomes is converted into double standard DNA. This genetic code²⁸. The provirus is a copy of retroviruses genome after. As result of its incorporation into host genome, the proviruses act as a template for DNA dependent RNA polymerase in cells. To create novel viral RNA genomes as well as shorter viral RNA genomes messenger RNA’S that are sub genomic. The single- stranded and translated into proteins the viral core components²⁹. A lipid bilayer membrane derived from the host cell and a virally encoded membrane make up the vision envelope. Each of the tetramer envelope protein complexes. The membrane components are made up of two non- covalently connected membranes. So (the outer envelope protein) and go 120 the inner envelope protein show (the transmembrane protein or TM) viral entrance is facilitated by the envelope complex binding to CD4, the primate's major cellular receptor lentiviruses³⁰. The outer envelope protein is involved in fusion of viral envelope with the cellular membranes whereas the trasmembrane protein, gp41, involved in fusion of viral envelope with the cellular membranes^31,32. The eangene encoded the envelope precursor protein, which is then proceeding by a cellular protease into envelope protein. The first viral components where made from viral mRNA that had been multiply spliced. The vitamin and Put protein impact the infectivity and release of cell free visions, respectively. ^33,34 appears to play a role in HIV replication in non- dividing cells³⁵. Soon after the diversity and sequence analysis of the initial isolates from various individuals the substantial heterogeneity of HIV isolates was noticed ³⁶. The term quasispecies were coined to describe the presence of sequence variation even within patients as a result of this discovery³⁷. The frequency distribution of specific viral alters during infection. The evolution of virus variations in Vivo is reflected in the capacity of viral isolates to replicate and replication potential³⁸. The low fidelity of reverse transcriptase paired with the extraordinary fast virus turnover in Vivo (latest estimates put virus generation at space of one per second) the emergence of novel viral varieties on a regular basis.^39-41

Treatment of Aids:

AIDS does not have a cure. The greatest choice is prevention. Furthermore, unlike pneumonia or typhoid, HIV infection spread more frequently as a result of deliberate behaviour patterns. Infection in blood transfusion patients, of course, is a new- born (from mother). The initial euphoria engendered by reports of protease inhibitors efficacy was quickly tempered by the sobering realization that sticking to these complex and hazardous regimens was often a difficult undertaking⁴². The inability to tolerate medication side effects, dread of the medication high toxicity, concern that medication use lead to unwelcome disclosure of illness, and disturbance of daily routine have all been cited as reason for patient no adherence⁴³. The enzyme linked immuno-sorbent assay is a commonly used AIDS diagnostic test (ELISA). for the some reason, many people put off starting treatment or refuse to use protease inhibitors despite their doctors advice^44,45. The biological benefits of the recently proposed regimens for organize treatment interruption are currently being investigated⁴⁶. The impact of these treatment interruptions on adherence has yet to be determined. While the thought of medication free intervals may be appealing, increase adherence because patients have something to look forward to these authorized treatment breaks may also help to reduce the severity of the condition. Adherence by enabling patients to take charge of their own treatment. Drug vacation. patient who are unable to maintain adherence to treatment regimens may balm themselves and have a negative attitude. A feeling of failure on a personal level. Those who adder to but do not gaining the enormous health benefits that early media provided. Anger, betrayal, hopelessness, anxiety and dried may be experienced by those exposed to the miraculous new medication⁴⁷. Arnold and Selwyn.Have also discovered that, prior to HAART, all infected people. Faced the same fate: death from the infection. However, now that certain people are able to take use of it, the idea of fate being universal, uncompromising and inexorable has been supplanted by the idea of fate being unidirectional, unyielding and unavoidable. As fate gets more selective and changeable, one of tragedy. Something that can be influenced by individual decision and action. This concept has a lot of potential, however also leads to feeling of shame, remorse and blame⁴⁸. AIDS patients have antibodies to many more viruses and bacteria, including unusable ones like HTLC, than the general population, classifying HIV as a disease is arbitrary by the presence or titer of antibody, an etiologic agent of AIDS alone. Furthermore, this idea is incompatible with the antibodies typically follow a very predictable series of events than the virulence of the virus^49-51.

CONCLUSION:

There are significant continuities as well as discontinuities in the experience of living with HIV/ AIDS during the last two decades, as this review reveals. The advance made in the diagnosis, treatment, and clinical management of this disease since the beginning of the epidemic are cause for celebration. Patients, on the other hand, are still dealing with many of the same issues. As in the pre-HAART era, there are psychological issues, though they are less severe.in several guises. AIDS is effect on mental state of infected person. The person may undergo depression. The AIDS is sexually transmitted infections. It can be spread through the contact with infected patients. AIDS does not have cure. The greatest choice is prevention. A widely used diagnostic test AIDS is enzyme linked immuno-sorbent assay (ELISA). Treatment of AIDS with anti-retroviral drugs is only partially effective.

REFERENCE:

1. Siegel K, krauss B. Living with HIV infection: adaptive task of seropositive gay men. J Health SocBehav 1991, 32: 17-22.

2. Nokes k. Applying the chronic illeness trajectory model to HIV/AIDS. Such InqNuts pract 1991, 5: 197-204.

3. Jeu S. Psychosocial issues of AIDS long term survivors. Families Soc 1994, 75: 324-334.

4. Kobayashi, JS. The evolution of adjustment issue in HIV/AIDS. Bull menningerclin 1997, 61 (2.): 146-38.

5. Rabkin JG, ferrando S. A second life agenda: Psychiatric research issue raised by protease inhibitors treatment for people with the human deficiency virus or acquired immunodeficiency syndrom. Arch Gen psychiatry 1997, 54: 1049-1053.

6. Sowell RL, Philips KD, Grier J. Restructuring life to face the future: the perspective of men after a positive response to protease inhibitor therepy. AIDS patients care STDS 1998, 12: 33-42.

7. Centers for Disease control and prevention. update: trends in AIDS incidence- united state, 1996 Morbid Mortal WKly Rep 1997, 46: 861-867.

8. UNAIDS, WHO. Under Embargo. AIDS Epidemic update joint united Nation, programme on HIV/ AIDS (UNAIDS) and world health organisation (WHO). Geneva: December 2001.

9. Bassetti s, Battegay M, further H. et al. Why is highly active anti-retroviral therapy (HAART) not prescribed or discontinued? SWISS HIV cohort study. J acquire immune Deficsyndr 1999, 21: 114-119.

10. Maisels L, Steinberg J. Tobaisc. An investigation of why eligible patients do not receive HAART AIDS patient care 2001, 15: 185-191.

11. Herbert, B, Brownstone A, clanon K, Abercrombie P, Bangberg D. Combination anti-retroviral therapy: health care providers confront emerging dilemmas. AIDS care 2000, 12: 409-421.

12. Chesney MA, ICKOVICS J, Hecht FM, Sikia G, Rankin J. Adherence: a necessity for successful HIV combination therapy. AIDS 1999, 13 (SUPPLA): s271-s278.

13. Fogarty L, Roter D, Larson S, Burkaj, Gillespie J, levy R. Patients adherence to HIV medication regimens: a review of published and abstract reports. Patient Edvc coins 2002, 46: 93-108.

14. Cook JA, Cohen MH, Grey D, et al. Use of highly active anti-retroviral therapy in a cohort of HIV seropositive Women. Am J public Health 2002, 92: 82-87.

15. Jacobson LP, Gore ME, strathdee SA, phair JP, Riddler's, Detels R. Therapy naivete in the era of potent anti-retroviral therapy. J club Epidemial 2001, 54: 149-156.

16. Jeffe DB, Meredith KL, Mindy LM, Fraser VJ. Factors associated with HIV infected patients recognition and use of HIV medication. J acquir immune Deficsyndr Hum Retrovir 1998, 19: 359-360.

17. Mocroft A, Gill MJ, Davidson W, Philips AN. Are there gender differences in starting protease inhibitors, HAART and disease progression despite equal access to care? J Acquir immune Deficsyndr 2000, 24: 475-482.

18. Atklnson, J. H and Grant, I.(1994). Natural history of neuropsychiatric manifestation HIV disease. Psychiatric clinics of North America 17, 17-23.

19. HART, J, Einav, C, Weingarten, M.A and Stein, M (1990). the important of family support in a behaviour modification weight loss program. Journal of America Dietic association, 90, 1270-1271.

20. Sturat, R.B and DAVIS, B. (1972). slim chance in a fat world. Chicago, IL: Research press.

21. Wilcox, D.R.C., GILLAN, R and HARE, E.H (1965). do Psychiatric outpatient take their drugs? British Medical Journal,22, 790-792.

22. Nokes K. Revisiting how the chronic illness Framework can be applied to people living with HIV/ AIDS.schlnq Nuts pract 1998, 12: 27-31.

23. Bogart LM, Catz SL, Kelly JA. et al. Psychosocial issue in the era of new AIDS treatment from the perspective of person living with HIV.J Health psychol 2000, 5: 500-516.

24. Schultz MA Sanfort TG. HIV- positive people, risk and sexual behaviour. socsci Med 2000,50: 157-1588.

25. Barre- Sinoussi F. ChermannJc, Rey F, et al. Isolation of a T- lymphotropicretrovirus from patients risk for Acquir immune deficiency syndromes. Science (1983) 220: 863-70.

26. Popovic M, Sarngadhan MG, Read E, Gallo Rc, Detection isolation and continuous production of cytopathic retrovirus (HTLV-III) from patient with AIDS and pre AIDS Science 1984; 224: 500-04.

27. Hayami M, Ido E, minurat T, survey of simian immunodeficiency virus among non- human prvote population. Cure Top Microbial Immunol 1994; 188: 1-20.

28. Myers G. Maclnnes K, Korber B. The emergence of simian/ human immunodeficiency viruses. AIDS Res Hum Retrovir 1992; 8: 373-85.

29. Bukrinsky MI, Haggerty S, Dempsey MP, et al. A nuclear localisation signal within HIV-1 matrix protein that governs infection of non - dividing cells. Nature 1993; 365: 666-68.

30. Weiss RA. Cellular receptor and viral glycoprotein involved in retrovirus entry. In :LevyJA, ed. The Retrovirifae, vol3.New York plenum, 1993; 1-108.

31. Coffin JM. Structure and classification of retrovirus. I n: levy JA, ed the retroviridaevol 1. New York Plenum, 1992: 29-50.

32. Levy JA. Pathogenesis of human immunodeficiency virus Infections Microbial Rev 1993; 57: 183-289.

33. Strebel K, Davgherty D, clause K, Cohen D, folks T, Martin MA . The HIV a (SOR) gene product is essential for virus infectivity. Nature 1987; 328: 728-30.

34. Strebel K, Kimkait T, Martin MA. A novel gene of HIV-1, Vpu and it's 16- kilodalton product. Science 1988; 241; 1221-23.

35. Bukrinsky MI., Sharova N, Derpsey MP. active nuclear import of human, immunodeficiency virus type 1 proteingration complexes pro Nal-1 Acadsci USA 1992; 89: 6580-84.

36. Benn S, Ruttedge R, Folks T, et al genomic heterogeneity of AIDS retroviral isolates from north America and Zaire science 1985; 230: 949-57.

37. Goodenow M, Hurt T, Saurin W, Kwoks, Sninsky J, wain- Hobson S HIV-I isolates are rapidly evolving quasispecies; evidence for viral mixture and preferred nucleotide substitution. J acquire immune Deficsyndr 1989; 2; 344-52.

38. Cannot RI, Ho DD. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Viral 1994; 64: 4400-08.

39. Wei X. Gosh SK, Taylor ME, et al viral dynamic in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22.

40. Ho DD, Neumann AV, perelson As, et al Rapid turnover of plasma variation and CD4 lymphocytes in HIV-l infection. Nature 1995; 373: 123-26.

41. Caffin J. Genetic diversity and evolution of retroviuses. Cure topic Microbial Immunol 1992; 176; 143-64.

42. Chesney MA. factors affecting adherence to anti-retroviral therapy. CL n Infect Dis 2000, 30(suppl2): s 171-s 176.

43. D' ArminioMonteforte A, lepri AC, Rezza G, et al. Insight into the reason of discontinuation therapy (HAART) regimen in a cohort of anti-retroviral naive patients I.CO.N.A. studygroup. italian cohort of anti-retroviral naive patients. AIDS 2000,14: 499-507.

44. Gold RS, Hinchy J, Batrouney CG. The reasoning behind decision not to take up anti-retroviral therapy in Australian infected with HIV. Int STD AIDS 2000,11: 361-370.

45. Izopet J, Massip P, Sourish, et al. Shift in HIV resistance and short term antiviral effect following a new salvage regimen. AIDS 2000, 14: 2247-2255.

46. Maggiolo, F, Callengaro A, Gregis G, et al. Strategic selective treatment in highly pre- treated HIV patients harbouring multiply resistant virus. AIDS 2002, 16: 289-299.

47. kelly JA, otto - Salaj LL, sikkema KJ, pinkerton SD, Bloom FR. Implications OF HIV treatment advances For behavioral research on AIDS protease inhibitors and the new challenges. in HIV primary prevention. Health Psycho" 1998, 17: 310 319.

48. Selwyn P, Arnold R. from fate to tragedy: the changing meanings of life death and AIDS, Ann Intern Med 1998, 129: 899-902.

49. Mind, C. and white D. O (1984) viral pathogenesis and Immunology (Blackwell, Oxford).

50. Fvans A.S. (1989) J. Acquired Immune Deficiency -syndr 2, 107 -113.

51. Duesberg, P.H. (1989) J. Acquired Immune Deficsyndr 2, 514-517.

Received on 16.05.2022 Modified on 31.05.2022

Res. J. Pharmacology and Pharmacodynamics.2022;14(3):155-158.

DOI: 10.52711/2321-5836.2022.00026